Don’t see what you’re looking for? Use the search box on MDA’s Quest magazine.
Israeli biotechnology company BrainStorm will test its adult stem cells, derived from bone marrow, in 48 ALS patients at three sites
Posted on Friday, June 13, 2014 - 10:06, By: Margaret Wahl
Israeli biotechnology company BrainStorm Cell Therapeutics has enrolled the first participant in a phase 2, U.S.-based trial of adult stem cell transplantation to treat amyotrophic lateral sclerosis (ALS).
Themes discussed at a recent symposium included immune system modulation, combatting toxic proteins and genetic material, replacing or repairing damaged cells, and improving muscle function
Posted on Friday, December 20, 2013 - 10:25, By: Margaret Wahl
"We are undoubtedly slowing down the MND [motor neuron disease] supertanker, and can start to see how we might turn it around for the first tim," said Martin Turner, senior clinician scientist at the University of Oxford (United Kingdom), on research being reported on at the 24th International...
Three short items about the state of ALS science: BrainStorm’s upcoming US stem-cell trial; modifying ALS progression; a blood-based biomarker test
Posted on Wednesday, October 9, 2013 - 05:00, By: Amy Madsen
This roundup of recent amyotrophic lateral sclerosis (ALS) research and clinical trials news includes:
Research news about clinical trials testing a Parkinson’s drug and stem cells in ALS reported at the 65th annual meeting of the American Academy of Neurology
Posted on Friday, March 22, 2013 - 16:45, By: Amy Madsen
Update (July 30, 2013): BrainStorm Cell Therapeutics announced in a July 29, 2013, press release that the European Commission has granted Orphan Drug Designation to the company’s NurOwn stem cell therapy for the treatment of ALS.
Thanks to promising early safety results, BrainStorm’s phase 1-2 safety trial of adult stem cells has been advanced to a phase 2a dose-escalating trial
Posted on Wednesday, January 9, 2013 - 11:05, By: Amy Madsen
Update (June 10, 2013): BrainStorm announced in a June 10, 2013, press release that enrollment has been completed for the company’s ongoing phase 2a trial of NurOwn adult stem cell therapy in ALS.
NurOwn stem cell technology, currently being tested in Israel, appears safe and seems to improve breathing, swallowing and muscle strength
Posted on Monday, January 23, 2012 - 09:41, By: Amy Madsen
Preliminary data reported Jan. 17, 2012, by BrainStorm Cell Therapeutics demonstrate that the biotechnology company's experimental NurOwn stem cell technology has not caused any significant adverse side effects in a phase 1-2 clinical trial in amyotrophic lateral sclerosis (ALS). In addition,...
Posted on Friday, July 1, 2011 - 13:37, By: ALSN Staff
Eating and breathing: A possible 'synergistic' effect in ALS
Initial results of a multicenter pilot study to evaluate nutritional requirements and early intervention for breathing problems in ALS are helping scientists determine how physical factors such as body mass, diet and activity affect the...